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Background: The present study evaluated the efficacy and safety of human embryonic stem cell (hESC) therapy in
patients with CP.
Materials and methods: This analysis included patients (30 days-18 yr) with documented diagnosis of CP. The
study consisted of four treatment phases (T1, T2, T3, T4) separated by gap phases. Efficacy of hESC therapy was
evaluated based on Gross Motor Function Classification Scores Expanded and Revised (GMFCS-E & R; 1-good to
5-bad).
Results: Ninety one patients were included and all received hESC therapy in T1, 66 patients returned for T2, 38
patients for T3, and 15 patients for T4. Overall, 30.2% patients achieved GMFCS-E & R score 1 during the study with
different number of patients achieving GMFCS score 1 by the end of each treatment phase (T1: 6 [6.6%]; T2: 7
[10.6%]; T3: 11 [28.9%]; and T4: 5 [33.3%]). All patients in up to 2 yr (n = 10), 2-4 yr (n = 10), 4-6 yr (n = 9), and 6-12 yr
(n = 8) age groups except one of the 5 patients in the age group of 12-18 yr transitioned from GMFCS-E & R score
5 to lower scores by end of T1. Most patients transitioned to GMFCS-E & R score 2 (n = 34) from higher scores by
end of T2. Eleven patients achieved GMFCS-E & R score 1 by end of T3. No serious adverse events were observed.
Conclusion: Use of hESC therapy in patients with CP is effective and safe. hESC therapy has demonstrated
significant improvement in GMFCS-E & R scale.
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Cerebral palsy (CP), a leading cause of disability among
children is caused by damage to the developing brain.
According to the Centers of Disease Control (CDC),
prevalence of CP around the world ranges from 1.5 to
more than 4 per 1,000 live births [1]. In India, the preva-
lence rate of CP per 100,000 population was estimated
to be 282.70 (95% CI 208.43-374.82) in a cross-sectional
observation study [1].
Stem cell therapy has the potential to overcome
neurological impairments caused by CP. This is achieved
by their ability to replace damaged cells of the nervous
system. The replacement and transformation potential is
higher with embryonic stem cells (ESC) as compared
with other types of stem cells [2]. Human embryonic
stem cells (hESCs), which are obtained from early pre-* Correspondence: geetashroff@hotmail.com
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unless otherwise stated.implantation stage human fertilized ovum are self
renewing cells capable of differentiating into any cell
type in the human body. This ability has led to their ex-
tensive use in the treatment of several neurodegenerative
and neurological disorders [3].
Embryonic stem cells have shown favorable results
in animal models. Zhang et al found favorable post-
implantation histological changes in a rat model 24 hr
after injury with survival of the transplanted cells, migra-
tion, and differentiation of these cells towards neural cell
types [4]. Ma et al showed that embryonic-derived stem
cells possessed the ability to migrate to the injury site
and improve learning ability and memory completely
eight months after the injury [5]. Daadi et al demon-
strated a significant (p < 0.05) improvement in loco-
motor deficits due to CP in animal model after 1 month
of stem cell transplantation [6]. Liao et al showed that
transplantation of cord blood stem cells in animal
models showed improvement in neonates with hypoxicThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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resulted from anti-inflammatory effects, release of neuro-
trophic factors, and by the stimulation of endogenous
neurogenesis [7].
However, there is a paucity of data on use of hESCs in
patients with CP. The present study evaluated the effi-
cacy of hESC therapy in patients affected with CP using
Gross Motor Function Classification System- Expanded
and Revised (GMFCS-E & R) in patients aged up to
18 yr. The safety of hESC therapy in the treated patients
was assessed in terms of adverse events (AEs) docu-
mented at any time during the course of therapy.
Materials and methods
Study characteristics
This study was a retrospective analysis of a total cohort
of 101 patients with CP who were treated with hESC
conducted from 01 October 2007 to 31 July 2013 in
New Delhi, India.
Ethics statement
The study protocol was approved by the Independent
Ethics Committee (IEC). The institutional committee for
stem cell research and therapy of Nutech Mediworld re-
ported the clinical study to National Apex Body. The
study was conducted in accordance to the Declaration of
Helsinki [8].
A written informed consent was obtained from the pa-
tients/parents/guardians prior to the treatment.
Study population
Patients aged 30 days to 18 yr and with a documented
diagnosis of CP who provided a written informed con-
sent were included. Patients above the age of 18 yr were
excluded.
Cell culture and differentiation
The cells are cultured and maintained as per our propri-
etary in-house technology (United States Granted Patent
No US 8592, 208, 52) in a good manufacturing practice
(GMP), good laboratory practice (GLP) and good tissue
practice (GTP) certified laboratory. The cell lines are
free of animal product and are chromosomally stable.
Two directed cell lines, non-neuronal and neuronal were
obtained from a single, spare, expendable, pre implant-
ation stage fertilized ovum taken during natural in vitro
fertilization (IVF) process with due consent. The detailed
cell culture and differentiation techniques have been elab-
orated elsewhere (detailed compositions comprising hu-
man embryonic stem cells and their derivatives, methods
of use, and methods of preparation is available at http://
patentscope.wipo.int/search/en/WO2007141657.
The priming injection of a pharmaceutical compos-
ition contained about 750,000 to 80 million hESC and/or their derivatives, resuspended in a volume of about 0.25 -
1.0 ml of sterile normal saline. It was estimated that 1 mL of
cells dosage contained 3.5 × 106 hESCs; therefore, 0.25 mL
contained 14 × 105 hESCs. The concentration of the cells at
the last stage was 2.5-3.5 million cells per mL. These cells
were further stored in 1 mL, 2 mL, 5 mL and 10 mL syrin-
ges at -20°C for further clinical use. When required the pre-
filled frozen syringes were thawed by placing the syringes
inbetween palms of the hands till they attain the body
temperature prior to the transplantation. After this slow
thawing process, they were injected into the patient under
aseptic conditions. A quality check was performed on the
stored cell batches which included integrity, viability and
microbial contamination. The cells were characterized and
the transplanted cells were octamer-binding transcription
factor 4 positive (OCT4 + ve); Stage-specific embryonic anti-
gen 3 (SSEA3) + ve; NANOG+ ve; SOX+ ve; β actin + ve;
β-human chorionic gonadotropin (β–HCG) + ve; alkaline
phosphatase + ve; CD 34+ ve; Nestin + ve; GAF+ ve; NeuN+
ve and transfer gene (TRA) –ve. The characterization
was done by fluorescence-activated cell sorting (FACS),
polymerase chain reaction (PCR) and immunofloures-
cence (Nikkon Ellipse E200; BD Acuri, Biorad T 100
Thermal cycle).
Study design
The study consisted of four treatment phases (T1, T2,
T3, T4) with each phase separated by a gap phase. After
an established diagnosis of CP through developmental
quotient (DQ) and Single Photon Emission Computed
Tomography (SPECT) scan, the patients were tested for
hypersensitivity reactions with hESC (0.25 mL hESC
injected subcutaneously). The SPECT scan was obtained
using Millennium MG, GE and was carried out before
or within 7 to 10 days of hESC therapy initiation and
thereafter at the end of each treatment phase. The pa-
tients received an IV injection of hexa methyl propylene
aminoxime (HMPAO) into antecubital vein before the
SPECT scan. After 15 min to 2 hr of receiving the injec-
tion, the patients were placed in a supine position with
the orbitomeatal line positioned vertically centered in
the field of view.
Following safety evaluations, patients entered the first
treatment phase (T1, 8 weeks) where 0.25 mL (<4 mil-
lion cells) hESCs were administered through intramus-
cular (IM) route once daily and 1 mL of hESC (<16 million
cells) was administered twice every 7 days through intra-
venous (IV) route. The IM route was used for priming and
the IV route was used to facilitate faster transplantation
and migration of the hESCs to the affected area. In
addition, each patient received a dose of hESCs by caudal
route which could be repeated every 5-14 days. hESCs
were administered through the caudal route to ensure they
reach the spinal fluid and regenerate the spinal cord and
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drops if required 0.25 mL two times a week (administered
in patients with visual impairment), nasal spray 0.25 mL
two times a week (to facilitate migration of hESCs to the
brain through the olfactory nerves), oral drops, ear drops
of hESCs were also given to the patients (as per their clin-
ical condition). They were also given deep spinal muscle
injections at the back of the neck and base of the spine
once a week. The visually impaired children were also
given retro bulbar injections. After a gap period of 3-6
months, the patients entered second and third treatment
phase (T2 and T3) where they were administered the same
dosage regime as T1. Both T2 and T3 lasted for 4 weeks
and were separated by a gap phase of 3-6 months. The in-
jections could be increased for an individual, if required.
The next treatment phase, T4 was performed after a
gap period of 6-12 months. The dosage regimen of T4
was similar to that of T2 however; the IV dose of hESC
was increased by 1 mL. The dose of hESCs administered
was changed over a period of time as per the patient’s
condition and repeated dose of hESCs was administered
with extra caution. All the patients received physiother-
apy and rehabilitation program in addition to hESC ther-
apy. The study design is illustrated in Figure 1.
In the present study, no control group or placebo
group was included. The patient and prognosis observed
was considered as a control.
Variables for analysis
Efficacy evaluation
The efficacy of hESC therapy was evaluated based on
the GMFCS-E & R scores (1[good] to 5[bad]). These
scores were collected at baseline and after completion of
each treatment phase.
Safety evaluation
The safety of hESC therapy was evaluated by assessing
the AEs experienced by patients during the study. AnyFigure 1 Study design and disposition of subjects.disabling symptom/sign that a patient suffered after the
test dose was given was considered as an AE. The med-
ical staff of Nutech Mediworld carefully examined the
patients for any AEs keeping the ones related to hESCs
in mind. These AEs included teratomas, and antigen-
antibody reactions.
Data validation
The data for all the patients was validated by Moody
International (DOC NO MIC/APR/2010/01), and Qual-
ity Austria Central Asia Pvt Ltd (DOC NO Q ACA/
OCT/2013/26), accreditation company. These compan-
ies were allowed to examine the medical and statistical
data present at the institute and were also able to meet
the patients.
Statistical analysis
No formal sample size was calculated for this study.
Each case was assessed at admission or soon after ad-
mission to determine the pre-therapy status of the case.
The GMFCS-E & R scores were calculated for each pa-
tient (91 cases). All patients were classified into different
age groups viz ≤2 yr; 2 to 4 yr; 4 to 6 yr; 6 to 12 yr; and
12 to 18 yr. The analysis was based on frequency or
count of the cases placed in different groups. The safety
analyses were performed on safety population (patients
who took at least one dose of hSEC). All the statistical
tests were conducted at 5% level of significance. Statis-
tical analysis was performed using SPSS 19 software
(IBM Corporation, Armonk, NY).
Results
Study patients
A total of 91 patients were included in the study and all
patients were started on intensive dosing. Most patients
included in the study were males (71.4%) aged up to
18 yr. All 91 patients were included in T1. Of the 91 pa-
tients, 66 patients returned for T2, 38 patients for T3,
and 15 patients for T4. The number of patients per
treatment phase is illustrated in Figure 1. The total treat-
ment days in T1 were 60 days, in T2 were 30 days, in
T3 were 33 days, and in T4 were 29 days.
Efficacy evaluation
The efficacy of hESC therapy was assessed by evaluating
the GMFCS-E & R score at the end of each treatment
phase. Each patient who received hESC therapy at the
beginning of the study showed a change in GMFCS-E &
R score for better between baseline and end of T4. The
improvement in GMFCS-E & R score by the end of each
treatment period is presented in Table 1.
Overall, of the 91 patients who received hESC therapy
in T1, 6 patients (6.6%; 4-6 yr- 1 patient; 6-12 yr- 3 pa-
tients; 12-18 yr- 2 patients) were at GMFCS-E & R score
Table 1 GMFCS-E & R scores of the patients in each treatment phase
Treatment
phase
Age group Number of patients
GMFCS scores (start of session) GMFCS scores (end of session)
1 2 3 4 5 1 2 3 4 5
T1 (n = 91)
≤2 yr (n = 12) 0 0 2 0 10 0 3 5 4 0
2-4 yr (n = 14) 0 0 1 3 10 0 2 7 5 0
4-6 yr (n = 21) 0 5 2 5 9 1 8 9 3 0
6-12 yr (n = 27) 1 3 8 7 8 3 11 10 3 0
12-18 yr (n = 17) 0 4 2 6 5 2 8 6 0 1
Overall 1 12 15 21 42 6 32 37 15 1
T2 (n = 66)
≤2 yr (n = 11) 0 3 5 3 0 0 6 3 2 0
2-4 yr (n = 11) 0 1 6 4 0 1 1 7 2 0
4-6 yr (n = 12) 0 5 4 3 0 1 7 2 2 0
6-12 yr (n = 21) 1 8 10 2 0 3 13 5 0 0
12-18 yr (n = 11) 0 5 5 1 0 2 7 1 1 0
Overall 1 22 30 13 0 7 34 18 7 0
T3 (n = 38)
≤2 yr (n = 6) 0 2 2 2 0 0 3 3 0 0
2-4 yr (n = 10) 0 3 5 2 0 2 5 2 1 0
4-6 yr (n = 7) 0 4 1 2 0 2 3 1 1 0
6-12 yr (n = 9) 1 5 3 0 0 3 6 0 0 0
12-18 yr (n = 6) 2 3 0 1 0 4 1 0 1 0
Overall 3 17 11 7 0 11 18 6 3 0
T4 (n = 15)
≤2 yr (n = 5) 0 4 1 0 0 2 3 0 0 0
2-4 yr (n = 4) 0 2 2 0 0 2 1 1 0 0
4-6 yr (n = 2) 0 0 2 0 0 0 1 1 0 0
6-12 yr (n = 1) 0 1 0 0 0 0 1 0 0 0
12-18 yr (n = 3) 1 1 1 0 0 1 1 1 0 0
Overall 1 8 6 0 0 5 7 3 0 0
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E & R score of 5 at the beginning of T1; of which 41 pa-
tients transitioned to lower scores by the end of T1. By
the end of T1, 37 (up to 2 yr- 5 patients; 2-4 yr- 7 pa-
tients; 4-6 yr- 9 patients; 6-12 yr- 10 patients; 12-18 yr-
6 patients) transitioned to GMFCS-E & R score 3 and 32
(up to 2 yr- 3 patients; 2-4 yr- 2 patients; 4-6 yr- 8 pa-
tients; 6-12 yr- 11 patients; 12-18 yr- 8 patients) to
GMFCS-E & R score 2. All patients in the age group of
up to 2 yr (10 patients), 2-4 yr (10 patients), 4-6 yr (9
patients), and 6-12 yr (8 patients) transitioned from
GMFCS-E & R score 5 to lower scores by the end of T1.
Four of the 5 patients with a GMFCS-E & R score 5 in
the age group of 12-18 yr transitioned to lower scores by
the end of T1 (Table 1).
Overall, 66 patients received hESC therapy in T2, 7
(10.6%; 2-4 yr and 4-6 yr- 1 patient each; 6-12 yr- 3 pa-
tients; and 12-18 yr- 2 patients) were at GMFCS-E & R
score of 1 by the end of T2. Of the 30 patients (up to
2 yr- 5 patients, 2-4 yr- 6 patients, 4-6 yr- 4 patients, 6-12 yr- 10 patients, and 12-18 yr- 5 patients) with a
GMFCS-E & R score of 3 at the beginning of T2, 12 pa-
tients transitioned to lower GMFCS-E &R scores by the
end of T2. By the end of T2, most patients transitioned
to GMFCS-E & R score 2 (34 patients) (Table 1).
Of the 38 patients who received hESC therapy inT3,
11(28.9%; 2-4 yr- 2 patients; 4-6 yr- 2 patients; 6-12 yr-
3 patients; 12-18 yr- 4 patients) were at GMFCS-E & R
score of 1 by the end of T3. Majority of the patients who
scored 4 on GMFCS-E & R scale (up to 2 yr-2 patients,
2-4 yr- 2 patients; and 4-6 yr- 2 patients; 12-18 yr- 1 pa-
tient) at the beginning of T3; transitioned to lower
scores (Table 1).
In the last treatment phase T4, hESC therapy was re-
ceived by 15 patients and 5 (33.3%; up to 2 yr- 2 pa-
tients; 2-4 yr- 2 patients; 12-18 yr- 1 patient) were at
GMFCS-E & R score of 1 by the end of T4. One of the 4
patients with a GMFCS-E & R score 2 in the age group
of up to 2 yr transitioned to a lower GMFCS-E & R
score by the end of T4. Three of 6 patients (up to 2 yr-
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1 patient) transitioned to lower GMFCS-E & R scores by
the end of T4 (Table 1).
Change in the score (worse, no change, and better)
was assessed to evaluate the effect of hESC therapy. All
patients of ≤2 yr and 12-18 yr age group showed an im-
provement in score by at least one score by the end of
T1. Higher proportion of patients from the age groups
of 2-4 yr (92.9%), 4-6 yr (90.5%), and 6-12 yr (92.3%)
showed an improvement in score by the end of T1
(Table 2). In addition, 100% female patients (26/26) and
92.3% of male patients (60/65) showed an improvement
in GMFCS-E & R score by at least one score by the end
of T4.
In addition to GMFCS-E & R scores, we also analyzed
the cognitive skills of the patients using additional param-
eters. The cognitive skills of all the patients was assessed
by the end of T4 using 11 parameters (problem solving,
following commands, smiling, recognition/awareness, eye
contact, aggression, speech, feeding, toilet training, daily
living skills, and defense mechanism). This assessment
was done to evaluate the improvement in cognition and
functional recovery of the patients.
Overall, 69% of the patients showed an improvement
in cognitive skills (Figure 2). Improvements in parameters
which were documented using an in house developed
scoring system such as smiling (81.7%), recognition/
awareness (80.3%), aggression (78.9%), and following com-
mands (74.5%) were higher as compared with other
parameters.
Eight patients had hearing impairment of which five
were either totally deaf or heard sounds close to the ear.
All eight patients showed improvement by the end of
T4. A total of 59 patients had seizures before receiving
treatment, of which 45 had seizures multiple times a day
to 1-2 times every other day. All patients were seizure
free however; one patient continued to have seizures
every other day by the end of T4.
Overall, 29 patients scored 1, 50 patients scored 2, 12
patients scored 3, and none scored 4 and 5 on the
GMFCS-E & R scale by the end of T4. A significantTable 2 Number of cases scoring differently by at least






Alteration in the score at least
by 1 score [n (%)]
Worse No change Better
Up to 2 yr 12 0 (0) 0 (0) 12 (100)
2 to 4 yr 14 0 (0) 1 (7.1) 13 (92.9)
4 to 6 yr 21 0 (0) 2 (9.5) 19 (90.5)
6 to 12 yr 27 0 (0) 2 (7.4) 25 (92.6)
12 to 18 yr 17 0 (0) 0 (0) 17 (100)association (p < 0.05) between the severity of cases and
whether or not they showed improvement in GMFCS-E
& R score was observed in the present study. All the pa-
tients had received physiotherapy prior to hESC therapy
and had shown no improvement.
We were able to do SPECT scan in all our patients be-
fore and after the therapy. The SPECT scan of the pa-
tients demonstrated improved perfusion after receiving
hESC therapy. The SPECT scan report of one of our pa-
tient is illustrated in Figure 3A and B.
Safety evaluation
The commonly experienced AEs included body pain,
diarrhea, chest congestion, throat infection, fever, itch-
ing, and swelling. A total of 9 patients (9/91; 9.9%) expe-
rienced AEs during T1 (swelling-1, itching-1, fever-4,
throat infection-1, and chest congestion-2), 2 patients
(2/66; 3%) experienced AEs during T2 (diarrhea-1, and
body pain-1), 1 patient (1/38; 2.6%) experienced AEs
during T3 (diarrhea-1) and no AE were reported in T4.
No serious AEs were reported during the study. The
AEs observed during the study are presented in Table 3.
Discussion
Cerebral palsy, a neurological disorder that affects chil-
dren leads to compromised mental health and motor
abilities. To our knowledge, this is the first study to as-
sess efficacy and safety of hESC therapy in patients with
CP. The use of hESCs has not been clinically viable in
the past due to difficulty in harvesting these cells in a
xeno free environment. However; we used a patented in-
house (Patent-WO 2007/141657A PCT/1B 2007 Pub-
lished 13 Dec 2007) methodology for the isolation of
hESC to explore their potential in the treatment of CP.
All the patients had come to our facility after not
benefitting from the physiotherapy and other traditional
therapies. At our facility, the patients were given hESC
therapy along with physiotherapy. The results of the
present study with hESC are promising and showed im-
provement in considerable number of patients assessed.
Bjorgaas et al showed that children with CP are often
prone to hyperactivity, conduct problems, peer problems
and show a prosocial behavior [9]. Children with CP also
show abnormal posture and movement problems. Al-
though motor function and posture problems are com-
mon among children with CP, emotional quality of life
(QoL) and social well being is affected in these children
to a significant extent [10]. According to a questionnaire
based study, the most important aspects of treating pa-
tients with CP included improvement in function, mo-
bility, activity, participation, and QoL [11].
Although several therapies are available for the treat-
ment of patients with CP, none have shown satisfactory
outcomes. Rehabilitation [12], physical therapy [13],
Figure 2 Cognitive skills by the end of the therapy.
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and oral motor therapy for patients with difficulty in
swallowing, drooling, chewing problems [15], and the
use of botulinum toxin A [16] are few therapies available
for the treatment of patients with CP. However; the use
of botulinum toxin A in patients with CP is still conflict-
ing. In our study, the rehabilitation programme was pro-
vided only during the therapy. hESCs transplantation
was the mainstay of the treatment. Though all the pa-
tients had undergone rehabilitation programme prior to
treatment with hESCs, but they were not benefited.
Neonatal hypoxic-ischemic brain injury is one of the
major causes of CP. Patients with CP experience loss of
oligodendrocytes and myelin. The neural stem cells and
glial progenitor cells (GPCs) have the ability to differen-
tiate to form oligodendrocytes, and astrocytes resulting
in improved outcomes in the treatment of CP [17]. Stem
cells replace the damaged neurons through a chain of re-
actions involving both exogenous and endogenous neu-
rons, glial cells, and endothelial cells. These cells act
synergistically to repair brain damage which may pos-
sibly have caused CP [18].
Studies related to the use of hESC therapy in patients
with CP are few however; the use of cord stem cells in
CP patients has been evaluated for efficacy in studies
from the past. Transplantation of cord stem cells in a
2.5 year old boy with CP demonstrated significant im-
provement in motor function at week 4 of therapy, nor-
mal EEG and partial recovery from vision loss at week 7
of therapy [19]. Another study examining the efficacy of
stem cells in a 6 year old CP patient showed significant
improvement in motor function within 6 months of
therapy and also showed cognitive, speech, and sensoryimprovements [20]. Chen et al demonstrated improve-
ments in gross motor function measurement scores, and
language quotients in patients with CP after 3 months
(p-0.011) and 6 months (p-0.001) of therapy with neural
stem cells [21].
The GMFCS-E & R scores include the age band of up
to 18 yr [22]. As per this revised scale, we included pa-
tients aged up to 18 yr for the evaluation of efficacy of
hESC therapy with GMFCS-E & R scores. The results
demonstrated that the use of hESC therapy in patients
with CP was beneficial. Overall, 30.2% patients achieved
a score of 1 on GMFCS- E& R scale by the end of T4 of
338 days. A total of 86 patients (94.5%) showed an im-
provement in GMFCS-E & R score by the end of T4
with hESC. The GMFCS-E &R scale does not consider
cognitive improvement as a parameter [23]; however,
cognition is an important concern for patients with CP.
In the present study we evaluated the improvements in
cognitive skills among patients who had received hESC
therapy. Overall, cognitive skills of the patients also
showed a significant improvement in 69% of the patients
included in the study. Of these, highest improvement
was observed in parameters including smiling (81.7%),
and recognition/awareness (80.3%) In addition to these
parameters, hESC therapy showed an improved vision in
patients (will be presented in a separate paper). Previous
studies have shown that stem cell therapy may be benefi-
cial in the treatment of visually impaired CP patients
[24]. The first clinical trial of autologous umbilical cord
blood reinfusion in children aged 12 mon to 6 yr with
CP is ongoing at the Duke Univeristy. In this random-
ized, double blind study the participants were/will be
treated with autologous cord blood reinfusion. The
Figure 3 SPECT scan of a cerebral palsy patient (grey - normal; red, pink and white - above normal; green, light/dark blue, black -
hypoperfused). A) Showing hypoperfused Regions before Receiving hESC Therapy. B) Improved Perfusion (reduced black areas) after Receiving
hESC Therapy.
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umbilical cord blood might facilitate neural cell repair
resulting in improved function. The study will be com-
pleted in 2016 [25].
Various studies have demonstrated the migration and
differentiation of hESCs derived progenitor cells at the
site of brain injury [5,26], raising the hope that hESC
therapy may eventually be developed to treat disorders
related to the central nervous system [27]. hESCs de-
rived precursors have ability to travel along the olfactory
system and contribute to neurogenesis [28]. A pre clin-
ical study by Ma et al showed that ESCs-derived cells
transplanted on hypoxic-ischemic encephalopathy (HIE)mouse model migrated into the injury site of the brain
and expressed neural stem cell differentiation markers
like Nestin and MAP-2 [5]. In another study by Liu et
al, the migration of transplanted embryonic mesenchy-
mal stem cells (eMSCs) derived from hESCs in an ische-
mic rat were tracked by staining the brain sections with
GFP antibody. The GFP-positive cells were observed in
the infarcted region, penumbra and striatum after two
days of cells injection. These cells expressed several
neuronal markers like MAP-2 and β-tubulin 3, indicat-
ing the neuronal differentiation of transplanted eMSCs
[29]. In a study by Yang et al, hESC-derived neurons
and their progenitors survived transplantation for
Table 3 Adverse events experienced by patients during
the study period
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Parkinson disease and contributed to the recovery of
locomotor function [26].
In our study, hESCs could have migrated to the hypo-
perfused areas of the brain after transplantation and
“home” in the affected regions. As observed in previous
studies, the process of homing is regulated by the com-
munication of the SCs with chemokines, cytokines, and
growth factors released from the site of injury [30,31].
A previously conducted study demonstrated that intra-
nasal application of MSCs resulted in the migration of
these cells to the olfactory bulb, cortex, hippocampus,
striatum, cerebellum, brainstem, and spinal cord of rats
with Parkinson’s disease. This study showed that 24% of
the cells survived for 4.5 months in the brain of the rats
resulting in substantial improvement of motor function,
of the forepaw 40-110 days after administration of
MSCs, and decreased concentrations of inflammatory
cytokines in the rats [32]. Various studies have also re-
ported migration and differentiation of hESCs after in-
traocular injection [33,34]. The size of the hESCs used
in our study is less than 1 μm facilitating them to easily
permeate through the parenchyma via blood brain bar-
rier. The route of administration determines the ability
of the hESCs to reach the affected areas of the brain.
These cells migrated to the affected area and showed an
improvement in perfusion that is evident from the ex-
tent of improvement in the patients reflected in the
SPECT scan. The changes in SPECT scan and GMFCS-E
& R scale may be exclusively due to hESC therapy. Fur-
ther, the transplanted hESCs could have remained viable
in the body of the patients. Recently, researchers from
Thailand have demonstrated that ESCs derived from
18 year old frozen embryos have ability to differentiate
into multiple cell types similar to those derived from
fresh embryos [35].In the present study no immunosuppresants were
used. The transplantation of hESCs showed no immune
response in the patients. This may be comparable to sur-
rogacy wherein a complete genetic stranger is accepted
in the host, grows, and is delivered by the host. hESC
therapy also improved the overall well being of the pa-
tients who participated in the study. Most patients who
were unable to perform daily activities as a result of CP
were able to perform them with lesser effort.
Conclusion
The use of hESC therapy in patients with CP is effective
and safe. hESC therapy has demonstrated significant im-
provement in GMFCS-E & R scale and most patients
transitioned to a better score after completing all the
four treatment phases. The use of hESC therapy showed
improvement in cognitive skills CP patients. However;
scarcity of data related to hESC therapy and its use in
the treatment of CP demands more research in this area.
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